What is pharmacoepidemiology?

Pharmacoepidemiology

Volumn , Issue , 2019, Pages 3-26

  Strom, Brian L ^a  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

Adverse drug effects; Adverse drug reactions; Drug crises; Drug regulation; Pharmacoepidemiology; Postmarketing drug surveillance

Indexed keywords

EID: 85089640311     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781119413431.ch1     Document Type: Chapter

References (188)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200-5.
2. Moore RD, Smith CR, Lietman PS. Increased risk of renal dysfunction due to interaction of liver disease and aminoglycosides. Am J Med 1986; 80: 1093-7.
3. Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In: Davies DM, ed. Textbook of Adverse Drug Reactions. Oxford: Oxford University Press, 1977, p. 44.
4. Strom BL. Integrating pharmacoepidemiology into the design and conduct of clinical trials. J Clin Res Drug Dev 1988; 2: 161-8.
5. Geiling EMK, Cannon PR. Pathogenic effects of elixir of sulfanilimide (diethylene glycol) poisoning. JAMA 1938; 111: 919-26.
6. Wallerstein RO, Condit PK, Kasper CK, Brown JW, Morrison FR. Statewide study of chloramphenicol therapy and fatal aplastic anemia. JAMA 1969; 208: 2045-50.
7. Meyler L. Side Effects of Drugs. Amsterdam: Elsevier, 1952.
8. Erslev AJ, Wintrobe MM. Detection and prevention of drug induced blood dyscrasias. JAMA 1962; 181: 114-19.
9. Cluff LE, Thornton GF, Seidl LG. Studies on the epidemiology of adverse drug reactions. I. Methods of surveillance. JAMA 1964; 188: 976-83.
10. Miller RR, Greenblatt DJ. Drug Effects in Hospitalized Patients. New York: John Wiley & Sons, Inc, 1976.
11. Caranasos GJ, Stewart RB, Cluff LE. Druginduced illness leading to hospitalization. JAMA 1974; 228: 713-17.
12. Lenz W. Malformations caused by drugs in pregnancy. Am J Dis Child 1966; 112: 99-106.
13. Wardell WM. Therapeutic implications of the drug lag. Clin Pharmacol Ther 1974; 15: 73-96.
14. Kono R. Trends and lessons of SMON research. In: Soda T, ed. Drug-Induced Sufferings. Princeton, NJ: Excerpta Medica, 1980, p. 11.
15. Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina: association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 1971; 284: 878-81.
16. Wright P. Untoward effects associated with practolol administration. Oculomucocutaneous syndrome. BMJ 1975; 1: 595-8.
17. Ticrynafen recalled. FDA Drug Bull 1980; 10: 3-4.
18. Suspension of benoxaprofen (Opren). BMJ 1982; 285: 519-20.
19. Strom BL, Carson JL, Morse ML, West SL, Soper KA. The effect of indication on hypersensitivity reactions associated with zomepirac sodium and other nonsteroidal antiinflammatory drugs. Arthritis Rheum 1987; 30: 1142-8.
20. Inman WHW. Study of fatal bone marrow depression with special reference to phenylbutazone and oxyphenbutazone. BMJ 1977; 1: 1500-5.
21. Committee on Safety of Medicines. Osmosin (Controlled release indomethacin). Current Problems, no. 11. London, 1983.
22. Barash CI, Lasagna L. The Bendectin saga: "Voluntary" discontinuation. J Clin Res Drug Devel 1987; 1: 277-92.
23. Strom BL, West SL, Sim E, Carson JL. The epidemiology of the acute flank pain syndrome from suprofen. Clin Pharmacol Ther 1989; 46: 693-9.
24. FDA ponders approaches to curbing adverse effects of drug used against cystic acne. JAMA 1988; 259: 3225-30.
25. Stern RS. When a uniquely effective drug is teratogenic: the case of isotretinoin. N Engl J Med 1989; 320: 1007-9.
26. Hertzman PA, Falk H, Kilbourne EM, Page S, Shulman LE. The Eosinophilia-Myalgia syndrome: the Los Alamos Conference. J Rheumatol 1991; 18: 867-73.
27. Meyboom RHB. The triazolam experience in 1979 in The Netherlands, a problem of signal generation and verification. In: Strom BL, Velo GP, eds. Drug Epidemiology and Postmarketing Drug Surveillance. New York: Plenum Press, 1992, pp. 159-67.
28. Triazolam's status in European Community. Lancet 1991; 338: 1586-7.
29. Brahams D. Triazolam suspended. Lancet 1991; 338: 938.
30. Triazolam hearing. Lancet 1992; 339: 1291.
31. Randall T. Penile, testicular, other silicone implants soon will undergo FDA review (news). JAMA 1992; 267: 2578-9.
32. Egger M, Smith GD, Imhoof H, Teuscher A. Risk of severe hypoglycaemia in insulin treated diabetic patients transferred to human insulin: a case control study. BMJ 1991; 303: 617-21.
33. Egger M, Smith GD, Teuscher AU, Teuscher A. Influence of human insulin on symptoms and awareness of hypoglycaemia: a randomised double blind crossover trial. BMJ 1991; 303: 622-6.
34. Colagiuri S, Miller JJ, Petocz P. Double-blind crossover comparison of human and porcine insulins in patients reporting lack of hypoglycaemia awareness. Lancet 1992; 339: 1432-5.
35. Jick H, Hall GC, Dean AD, Jick SS, Derby LE. A comparison of the risk of hypoglycemia between users of human and animal insulins. 1. Experience in the United Kingdom. Pharmacotherapy 1990; 10: 395-7.
36. Jick SS, Derby LE, Gross KM, Jick H. Hospitalizations because of hypoglycemia in users of animal and human insulins. 2. Experience in the United States. Pharmacotherapy 1990; 10: 398-9.
37. Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990; 147: 207-10.
38. Beasley CM, Dornseif BE, Bosomworth JC, et al. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. BMJ 1991; 303: 685-92.
39. Crane J, Pearce N, Flatt A, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. Lancet 1989; 1: 917-22.
40. Pearce N, Grainger J, Atkinson M, et al. Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81. Thorax 1990; 45: 170-5.
41. Grainger J, Woodman K, Pearce N, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further casecontrol study. Thorax 1991; 46: 105-11.
42. Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992; 326:501-6.
43. Rosenfield A, Maine D, Rochat R, Shelton J, Hatcher RA. The Food and Drug Administration and medroxyprogesterone acetate. What are the issues? JAMA 1983; 249: 2922-8.
44. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Breast cancer and depot-medroxyprogesterone acetate: a multinational study. Lancet 1991; 338:833-8.
45. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Depotmedroxyprogesterone acetate (DMPA) and risk of invasive squamous cell cervical cancer. Contraception 1992; 45: 299-312.
46. Nightingale SL. From the Food and Drug Administration: warnings issued on nonsedating antihistamines terfenadine and astemizole. JAMA 1992; 268: 705.
47. Ahmad SR. Antihistamines alert. Lancet 1992; 340: 542.
48. Rothman KJ, Funch DP, Dreyer NA. Bromocriptine and puerperal seizures. Epidemiology 1990; 1: 232-8.
49. Gross TP. Bromocriptine and puerperal seizures. Epidemiology 1991; 2: 234-5.
50. Finch RG. The withdrawal of temafloxacin: are there implications for other quinolones? Drug Saf 1993; 8: 9-11.
51. Nathani MG, Mutchnick MG, Tynes DJ, Ehrinpreis MN. An unusual case of amoxicillin/clavulanic acid-related hepatotoxicity. Am J Gastroenterol 1998; 93:1363-5.
52. Hunter EB, Johnston PE, Tanner G, Pinson CW, Awad JA. Bromfenac (Duract)-associated hepatic failure requiring liver transplantation. Am J Gastroenterol 1999; 94: 2299-301.
53. Moses PL, Schroeder B, Alkhatib O, Ferrentino N, Suppan T, Lidofsky SD. Severe hepatotoxicity associated with bromfenac sodium. Am J Gastroenterol 1999; 94:1393-6.
54. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-31.
55. Pahor M, Guralnik JM, Ferrucci L, et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet 1996; 348: 493-7.
56. Braun S, Boyko V, Behar S, et al. Calcium antagonists and mortality in patients with coronary artery disease: a cohort study of 11, 575 patients. J Am Coll Cardiol 1996; 28: 7-11.
57. Kostis JB, Lacy CR, Cosgrove NM, Wilson AC. Association of calcium channel blocker use with increased rate of acute myocardial infarction in patients with left ventricular dysfunction. Am Heart J 1997; 133: 550-7.
58. Jick H, Jick S, Derby LE, Vasilakis C, Myers MW, Meier CR. Calcium-channel blockers and risk of cancer. Lancet 1997; 349: 525-8.
59. Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL. Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer 1997; 80:1438-47.
60. Rosenberg L, Rao RS, Palmer JR, et al. Calcium channel blockers and the risk of cancer. JAMA 1998; 279: 1000-4.
61. Michels KB, Rosner BA, Walker AM, et al. Calcium channel blockers, cancer incidence, and cancer mortality in a cohort of U.S. women: the Nurses' Health Study. Cancer 1998; 83: 2003-7.
62. Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med 1996; 335: 290-1.
63. Piquette RK. Torsade de pointes induced by cisapride/clarithromycin interaction. Ann Pharmacother 1999; 33: 22-6.
64. Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride: impact of Food and Drug Administration regulatory action. JAMA 2000; 284: 3036-9.
65. Weatherby LB, Walker AM, Fife D, Vervaet P, Klausner MA. Contraindicated medications dispensed with cisapride: temporal trends in relation to the sending of "Dear Doctor" letters. Pharmacoepidemiol Drug Saf 2001; 10: 211-18.
66. Kramer MS, Lane DA. Aminorex, dexfenfluramine, and primary pulmonary hypertension. J Clin Epidemiol 1998; 51: 361-4.
67. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337: 581-8.
68. Kimmel SE, Keane MG, Crary JL, et al. Detailed examination of fenfluraminephentermine users with valve abnormalities identified in Fargo, North Dakota. Am J Cardiol 1999; 84: 304-8.
69. Strom BL, Berlin JA, Kinman JL, et al. Parenteral ketorolac and risk of gastrointestinal and operative site bleeding: a postmarketing surveillance study. JAMA 1996; 275: 376-82.
70. Feldman HI, Kinman JL, Berlin JA, et al. Parenteral ketorolac: the risk for acute renal failure. Ann Intern Med 1997; 126: 193-9.
71. Hennessy S, Kinman JL, Berlin JA, et al. Lack of hepatotoxic effects of parenteral ketorolac in the hospital setting. Arch Intern Med 1997; 157: 2510-14.
72. Garcia Rodriguez LA, Cattaruzzi C, Troncon MG, Agostinis L. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med 1998; 158: 33-9.
73. Mullins ME, Horowitz BZ, Linden DH, Smith GW, Norton RL, Stump J. Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers. JAMA 1998; 280: 157-8.
74. Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ 1996; 312: 83-8.
75. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-93.
76. WHO Technical Report Series. Cardiovascular Disease and Steroid Hormone Contraception. Geneva: World Health Organization, 1998.
77. de Bruijn SF, Stam J, Vandenbroucke JP. Increased risk of cerebral venous sinus thrombosis with third-generation oral contraceptives. Lancet 1998; 351: 1404.
78. Feenstra J, van Drie-Pierik RJ, Lacle CF, Stricker BH. Acute myocardial infarction associated with sildenafil. Lancet 1998; 352:957-8.
79. Kahn LH, Alderfer RJ, Graham DJ. Seizures reported with tramadol. JAMA 1997; 278:1661.
80. Jick H, Derby LE, Vasilakis C, Fife D. The risk of seizures associated with tramadol. Pharmacotherapy 1998; 18: 607-11.
81. Pereira SP, Williams R. Adverse events associated with Vitamin K1: results of a worldwide postmarketing surveillance programme. Pharmacoepidemiol Drug Saf 1998; 7: 173-82.
82. Misbin RI. Troglitazone-associated hepatic failure. Ann Intern Med 1999; 130: 330.
83. Vella A, de Groen PC, Dinneen SF. Fatal hepatotoxicity associated with troglitazone. Ann Intern Med 1998; 129: 1080.
84. Neuschwander-Tetri BA, Isley WL, Oki JC, et al. Troglitazone-induced hepatic failure leading to liver transplantation: a case report. Ann Intern Med 1998; 129: 38-41.
85. Gitlin N, Julie NL, Spurr CL, Lim KN, Juarbe HM. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med 1998; 129: 36-8.
86. Centers for Disease Control and Prevention. Suspension of rotavirus vaccine after reports of intussusception-United States, 1999. Morb Mortal Wkly Rep 2004; 53: 786-9.
87. Moynihan R. Alosetron: a case study in regulatory capture, or a victory for patients' rights? BMJ 2002; 325: 592-5.
88. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289: 1681-90.
89. Schulman SR. Rapacuronium redux. Anesth Analg 2002; 94: 483-4.
90. Kelly DL, Love RC. Ziprasidone and the QTc interval: pharmacokinetic and pharmacodynamic considerations. Psychopharmacol Bull 2001; 35: 66-79.
91. Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000; 343: 1826-32.
92. Lathrop SL, Ball R, Haber P, et al. Adverse event reports following vaccination for Lyme disease: December 1998-July 2000. Vaccine 2002; 20: 1603-8.
93. Joellenbeck LM, Zwanziger LL, Durch JS, Strom BL, eds.; for Committee to Assess the Safety and Efficacy of the Anthrax Vaccine. The Anthrax Vaccine: Is It safe? Does It Work? Washington, DC: National Academies Press, 2002.
94. Chen RT, Lane JM. Myocarditis: the unexpected return of smallpox vaccine adverse events. Lancet 2003; 362: 1345-6.
95. Topol EJ. Failing the public health-rofecoxib, Merck, and the FDA. N Engl J Med 2004; 351: 1707-9.
96. Shah RR. The significance of QT interval in drug development. Br J Clin Pharmacol 2002; 54: 188-202.
97. U.S. Food & Drug Administration. Drug Safety-Related Labeling Changes. http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/default.htm (accessed April 2019).
98. United States Government Accountability Office. FDA Drug Review: Postapproval Risks 1976-1985. GAO/PEMD-90-15, April 1990, p. 24.
99. Cross J, Lee H, Westelinck A, Nelson J, Grudzinskas C, Peck C. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999. Pharmacoepidemiol Drug Saf 2002; 11:439-46.
100. United States Government Accountability Office. Drug Safety: Improvement Needed in FDA's Postmarket Decision-Making and Oversight Process. GAO-06-402. March 2006. http://www.gao.gov/new.items/d06402. pdf (accessed April 2019).
101. Heerdink ER, Urquhart J, Hubert G, Leufkens HG. Changes in prescribed drug doses after market introduction. Pharmacoepidemiol Drug Saf 2002; 11: 447-453.
102. Wardell WM. Therapeutic implications of the drug lag. Clin Pharmacol Ther 1974; 15(1): 73-96.
103. US Food & Drug Administration. Prescription Drug User Fee Act (PDUFA). http://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/default.htm(accessed November 2010).
104. Berndt ER, Gottschalk AH, Philipson TJ, Strobeck MW. Industry funding of the FDA: effects of PDUFA on approval times and withdrawal rates. Nat Rev Drug Discov 2005; 4(7): 545-54.
105. Friedman MA, Woodcock J, Lumpkin MM, Shuren JE, Hass AE, Thompson LJ. The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA 1999; 281: 1728-34.
106. Kleinke JD, Gottlieb S. Is the FDA approving drugs too fast? Probably not-but drug recalls have sparked debate. BMJ 1998; 317: 899.
107. Lurie P, Woodcock J, Kaitin KI. FDA drug review: the debate over safety, efficacy, and speed. Medical Crossfire 1999; 1: 52-60.
108. Wood AJ, Stein CM, Woosley R. Making medicines safer-the need for an independent drug safety board. N Engl J Med 1998; 339: 1851-4.
109. Moore TJ, Psaty BM, Furberg CD. Time to act on drug safety. JAMA 1998; 279: 1571-3.
110. Institute of Medicine Committee on the Assessment of the US Drug Safety System. The Future of Drug Safety: Promoting and Protecting the Health of the Public. Washington, DC: National Academy of Sciences, 2007.
111. FDAnews. PDUFA IV fees will go to improve postmarket drug safety. FDAnews Drug Daily Bulletin 2008; 5. http://www.fdanews.com/newsletter/article?articleId=106457&issueId=11559 (accessed April 2019).
112. U.S. Food & Drug Administration. Food and Drug Administration Safety and Innovation Act (FDASIA). https://www.fda.gov/RegulatoryInformation/LawsEnforcedbyFDA/SignificantAmendmentstotheFDCAct/FDASIA/default.htm (accessed April 2019).
113. U.S. Food & Drug Administration. Generic Drug User Fee Amendments. https://www.fda.gov/ForIndustry/UserFees/GenericDrugUserFees/default.htm (accessedApril 2019).
114. U.S. Food & Drug Admniistration. Biosimilar User Fee Act (BsUFA). https://www.fda.gov/ForIndustry/UserFees/BiosimilarUserFeeActBsUFA/default.htm(accessed April 2019).
115. Congress.gov. H.R.6-21st Century Cures Act. https://www.congress.gov/bill/114thcongress/house-bill/6 (accessed April 2019).
116. Lee JAH, Draper PA, Weatherall M. Prescribing in three English towns. Milbank Mem Fund Quart 1965; 43: 285-90.
117. Muller C. Medical review of prescribing. J Chronic Dis 1965; 18: 689-96.
118. Meade TW. Prescribing of chloramphenicol in general practice. BMJ 1967; 1: 671-4.
119. Joyce CRB, Last JM, Weatherall M. Personal factors as a cause of differences in prescribing by general practitioners. Br J Prev Soc Med 1968; 22: 170-7.
120. Muller C. Outpatient drug prescribing related to clinic utilization in four New York City hospitals. Health Serv Res 1968; 3: 142-54.
121. Slone D, Shapiro S, Miettinen OS. Casecontrol surveillance of serious illnesses attributable to ambulatory drug use. In: Colombo F, Shapiro S, Slone D, Tognoni G, eds. Epidemiological Evaluation of Drugs. Littleton, MA: PSG, 1977, pp. 59-82.
122. Joint Commission on Prescription Drug Use. Final Report. Washington, DC: U.S. Government Printing Office, 1980.
123. Strom BL, Carson JL, Morse ML, Leroy AA. The Computerized Online Medicaid Analysis and Surveillance System: a new resource for post-marketing drug surveillance. Clin Pharmacol Ther 1985; 38: 359-64.
124. Inman WHW. Prescription event monitoring. Acta Med Scand Suppl 1984; 683: 119-26.
125. Strom BL, Members of the ASCPT Pharmacoepidemiology Section. Position paper on the use of purported postmarketing drug surveillance studies for promotional purposes. Clin Pharmacol Ther 1990; 48: 598.
126. Andrews EA, Avorn J, Bortnichak EA, et al.; ISPE. Guidelines for good epidemiology practices for drug, device, and vaccine research in the United States. Pharmacoepidemiol Drug Saf 1996; 5: 333-8.
127. ISPE. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf 2008; 17: 200-8.
128. Neutel CI. Privacy issues in research using record linkage. Pharmacoepidemiol Drug Saf 1997; 6: 367 -9.
129. Melton LJ III. The threat to medical-records research. N Engl J Med 1997; 337: 1466-70.
130. Mann RD. Data privacy and confidentiality. Pharmacoepidemiol Drug Saf 1999; 8: 245.
131. Andrews EB. Data privacy, medical record confidentiality, and research in the interest of public health. Pharmacoepidemiol Drug Saf 1999; 8: 247-60.
132. Mann RD. The issue of data privacy and confidentiality in Europe-1998. Pharmacoepidemiol Drug Saf 1999; 8: 261-4.
133. Califf RM. The need for a national infrastructure to improve the rational use of therapeutics. Pharmacoepidemiol Drug Saf 2002; 11: 319-27.
134. Congress.gov. H.R.1-Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Sec. 1013. Research on Outcomes of Health Care Items and Services. https://www.congress.gov/bill/108th-congress/housebill/00001 (accessed April 2019).
135. Agency for Healthcare Research and Quality. The Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) research network (U19). 2013. https://grants.nih.gov/grants/guide/rfa-files/RFAHS-13-009.html (accessed April 2019).
136. Kohn LT, Corrigan JM, Donaldson MS, eds. To Err Is Human: Building a Safer Health System. Washington, DC: National Academies Press, 2000.
137. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events: implications for prevention. JAMA 1995; 274: 29-34.
138. Brennan TA, Leape LL, Laird NM, et al. Incidence of adverse events and negligence in hospitalized patients: results of the Harvard Medical Practice Study I. N Engl J Med 1991; 324: 370-6.
139. Classen DC, Pestotnik SL, Evans R, Scott R, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. JAMA 1997; 277: 301-6.
140. Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients. JAMA 1997; 277: 307-11.
141. Phillips DP, Christenfeld N, Glynn LM. Increase in US medication-error deaths between 1983 and 1993. Lancet 1998; 351: 643-4.
142. Manasse HR. Increase in US medicationerror deaths (letter). Lancet 1998; 351: 1655.
143. Ferner RE, Anton C. Increase in US medication-error deaths (letter). Lancet 1998; 351: 1655-6.
144. Rooney C. Increase in US medication-error deaths (letter). Lancet 1998; 351: 1656-7.
145. Phillips DP, Christenfeld N, Glynn LM. Increase in US medication-error deaths (letter). Lancet 1998; 351: 1657.
146. McDonald CJ, Weiner M, Hui SL. Deaths due to medical errors are exaggerated in the Institute of Medicine report. JAMA 2000; 284: 93-5.
147. Leape LL. Institute of Medicine error figures are not exaggerated. JAMA 2000; 284: 95-7.
148. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349: 523-34.
149. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
150. Col NF, Pauker SG. The discrepancy between observational studies and randomized trials of menopausal hormone therapy: did expectations shape experience? Ann Intern Med 2003; 139: 923-9.
151. Grimes DA, Lobo RA. Perspectives on the Women's Health Initiative trial of hormone replacement therapy. Obstet Gynecol 2002; 100: 1344-53.
152. Whittemore AS, McGuire V. Observational studies and randomized trials of hormone replacement therapy: what can we learn from them? Epidemiology 2003; 14: 8-9.
153. Piantadosi S. Larger lessons from the Women's Health Initiative. Epidemiology 2003; 14: 6-7.
154. United States Government Accountability Office. New Drug Approval: FDA needs to enhance its oversight of drugs approved on the basis of surrogate endpoints. GAO Highlights, September 23, 2009. http://www.gao.gov/highlights/d09866high.pdf (accessed April 2019).
155. Federal Coordinating Council for Comparative Effectiveness Research. Report to the President and Congress on Comparative Effectiveness Research. Washington, DC: US Department of Health and Human Services, 2009.
156. National Institute for Health and Clinical Excellence. What We Do. http://www.nice.org.uk/aboutnice/whatwedo/what_we_do.jsp (accessed April 2019).
157. Reichert JM. Trends in development and approval times for new therapeutics in the United States. Nat Rev Drug Discov 2003;2(9): 695-702.
158. Haberman AB. Overcoming Phase II attrition problem. Genet Eng Biotechn N 2009; 29: 1.
159. Pharmaceutical Research and Manufacturers of America (PhRMA). Pharmaceutical Industry Profile 2003. Washington, DC:PhRMA, 2003, p. 75.
160. Pharmaceutical Research and Manufacturers of America (PhRMA). Pharmaceutical Industry Profile 2009. Washington, DC: PhRMA, 2003, p. 2.
161. Shafrin J. Cost to bring drug to market: $802m. Healthcare Economist, April 29, 2006. http://healthcare-economist.com/2006/04/29/802m (accessed April 2019).
162. Collier R. Drug development cost estimates hard to swallow. CMAJ 2009; 180: 279-80.
163. Ratanawijitrasin S, Wondemagegnehu E. Effective Drug Regulation: A Multicountry Study. Geneva: World Health Organization, 2002. http://archives.who.int/tbs/qual/s2300e.pdf (accessed April 2019).
164. Government of Canada. Health Canada. http://www.hc-sc.gc.ca/index-eng.php (accessed April 2019).
165. China Food and Drug Administration. https://en.wikipedia.org/wiki/China_Food_and_Drug_Administration (accessed April 2019)
166. Danish Medicines Agency. About Us. http://www.dkma.dk/1024/visUKLSForside.asp?artikelID=728 (accessed April 2019).
167. Norwegian Medicines Agency. About Us. http://www.legemiddelverket.net/templates/InterPage____16645.aspx (accessed April 2019).
168. Pacific Bridge Medical. Singapore's Pharmaceutical and Medical Device Regulatory Environment: 2005 Update. https://www.pacificbridgemedical.com/publication/singapore-8217-s-pharmaceutical-andmedical-device-regulatory-environment-2005-update (accessed April 2019).
169. New Zealand Medicines and Medical Devices Safety Authority. About Medsafe. http://www.medsafe.govt.nz/other/about.asp(accessed April 2019).
170. Central Drugs Standard Control Organization. About CDSCO. https://cdsco.gov.in/opencms/opencms/en/Home (accessed April 2019).
171. Reichert JM. Pharmacopolitics: drug regulation in the United States and Germany. N Engl J Med 2004; 350: 2220-1.
172. European Medicines Agency. About Us. https://www.ema.europa.eu/en/about-us (accessed April 2019).
173. Abraham J, Lewis G. Harmonising and competing for medicines regulation: how healthy are the European Union's systems of drug approval? Soc Sci Med 1999; 48: 1655-67.
174. European Medicines Agency. What We Do. https://www.ema.europa.eu/en/about-us/what-we-do (accessed April 2019).
175. Department of Health and Human Services, Office of Inspector General. Postmarketing Studies of Prescription Drugs. OEI-03-94-00760. Philadelphia, PA: OIG. May 1996, p. 11. http://oig.hhs.gov/oei/reports/oei-03-94-00760.pdf (accessed April 2019).
176. Rosendorff C. Prazosin: severe side effects are dose-dependent. BMJ 1976; 2: 508.
177. Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS. Prazosin: the first-dose phenomenon. BMJ 1976; 2: 1293-4.
178. Kaitin KI. Case studies of expedited review: AZT and L-Dopa. Law Med Health Care 1991; 19: 242-6.
179. Wastila LJ, Lasagna L. The history of zidovudine (AZT). J Clin Res Pharmacoepidemiol 1990; 4: 25-37.
180. Peck CC. Postmarketing drug dosage changes. Pharmacoepidemiol Drug Saf 2003;12: 425-6.
181. Temple RJ. Defining dose decrease. Pharmacoepidemiol Drug Saf 2003; 12: 151-2.
182. McKenzie MW, Marchall GL, Netzloff ML, Cluff LE. Adverse drug reactions leading to hospitalization in children. J Pediatr 1976; 89: 487-90.
183. May FE, Stewart RB, Cluff LE. Drug interactions and multiple drug administration. Clin Pharmacol Ther 1977; 22: 322-8.
184. Nelson WL, Fraunfelder FT, Sills JM, Arrowsmith JB, Kuritsky JN. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1985. Am J Ophthalmol 1986; 102: 606-11.
185. International Agranulocytosis and Aplastic Anemia Study. Risks of agranulocytosis and aplastic anemia: a first report of their relation to drug use with special reference to analgesics. JAMA 1986; 256: 1749-57.
186. Stewart RB, Forgnone M, May FE, Forbes J, Cluff LE. Epidemiology of acute drug intoxications: patient characteristics, drugs, and medical complications. Clin Toxicol 1974; 7: 513-30.
187. Eisenberg JM. New drugs and clinical economics: analysis of cost-effectiveness analysis in the assessment of pharmaceutical innovations. Rev Infect Dis 1984; 6(Suppl 4): 905-8.
188. Morse ML, Leroy AA, Gaylord TA, Kellenberger T. Reducing drug therapyinduced hospitalization: impact of drug utilization review. Drug Inf J 1982; 16: 199-202.